The relationship between PD-L1 expression and the re- sponse is a current topic because of the tumor response to the anti-PD1 antibody in patients who do not ...
Targ Oncol DOI 10.1007/s11523-015-0392-7
SYSTEMATIC REVIEW
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis Roberto Iacovelli 1 & Franco Nolè 1 & Elena Verri 1 & Giuseppe Renne 2 & Chiara Paglino 3 & Matteo Santoni 4 & Maria Cossu Rocca 1 & Palma Giglione 3 & Gaetano Aurilio 1 & Daniela Cullurà 1 & Stefano Cascinu 4 & Camillo Porta 3
# Springer International Publishing Switzerland 2015
Abstract Background Several clinical trials have reported that therapies targeting programmed death-1 (PD1) and its ligand (PD-L1) improve patient outcomes, while tumor response has been related to PD-L1 expression. Objective To investigate the prognostic role of PD-L1 expression in patients affected by renal cell carcinoma (RCC). Methods MEDLINE/PubMed, the Cochrane Library, and ASCO University were searched for studies investigating the prognostic role of PD-L1 expression in RCC. Data extraction was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results Six studies and 1323 cases were included in the final analysis. PD-L1 was expressed in 24.2 % of clear cell tumors compared to 10.9 % of non-clear cell tumors (p=0.002). In the overall population, a higher level of PD-L1 expression increased the risk of death by 81 % (HR; 1.81, 95 % CI 1.31– 2.49; p
